Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 171
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.02-172 - Effect of EGFR Inhibition on Bone Health in NSCLC Patients without Skeletal Metastasis
Author(s): Marcella Mandruzzato- Abstract
Loading... -
+
EP08.02-012 - Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea
Author(s): Beung-chul AHN- Abstract
Loading... -
+
EP08.02-023 - Differentiation Syndrome in a Patient with Non-Small-Cell Lung Cancer Harboring IDH2 Mutation Treated with Enasidenib.
Author(s): Bhoomika Sukhadia- Abstract
Loading... -
+
EP08.02-127 - Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
Author(s): Bin-Chi Liao- Abstract
Loading... -
+
EP08.02-024 - Research Efforts in Systemic Therapy of Lung Cancer With Brain Metastasis From 2015-21: A clinicaltrial.gov Registry Analysis
Author(s): Bindu Krishnappa Venugopal- Abstract
Loading... -
+
EP08.02-025 - Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial
Author(s): Byoung Chul Cho- Abstract
Loading... -
+
EP08.02-026 - Real-world Efficacy of EGFR-TKI in Advanced NSCLC and Clinical Predictors of Outcome in Maharaj Nakorn Chiangmai Hospital in Thailand.
Author(s): Chaiyut Charoentum- Abstract
Loading... -
+
EP08.02-027 - T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC
Author(s): Chih-Hsi Kuo- Abstract
Loading... -
+
EP08.02-028 - Germline HRR Mutations in Metastatic NSCLC and Impact on Progression-Free Survival: A Single-Center Retrospective Study
Author(s): Chetan Vakkalagadda- Abstract
Loading... -
+
EP08.02-134 - Real-world Efficacy of Dacomitinib in Patients with Previously EGFR-TKI Treated Non-small Cell Lung Cancer
Author(s): Chien-Yeh Chi- Abstract
Loading... -
+
EP08.02-031 - NRF2 Pathway Signature Predicts KEAP1/NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC
Author(s): Christoph Arolt- Abstract
Loading... -
+
EP08.02-095 - Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with Aumolertinib
Author(s): Chunling Liu- Abstract
Loading... -
+
EP08.02-032 - High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid
Author(s): Mónica Garzón Ibañez- Abstract
Loading... -
+
EP08.02-033 - Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study
Author(s): da zhao- Abstract
Loading... -
+
EP08.02-034 - OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L
Author(s): Daniel Breadner- Abstract
Loading... -
+
EP08.02-043 - The Current State of Biomarker Testing in Lung Cancer as Seen by Health Care Providers
Author(s): Daniel A. Saez- Abstract
Loading... -
+
EP08.02-035 - Clinical Utility of Liquid Biopsy After Progression to First and Second-Generation TKIs in Advanced EGFR Mutant NSCLC Patients
Author(s): David Heredia- Abstract
Loading... -
+
EP08.02-040 - Dacomitinib Induced Febrile Neutropenia: a Rare Serious Adverse Event
Author(s): Debapriya Mondal- Abstract
Loading... -
+
EP08.02-066 - Real-World Data on the Side Effects of Alectinib, Brigatinib and Lorlatinib
Author(s): Debra Montague- Abstract
Loading... -
+
EP08.02-169 - Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation
Author(s): Dian Sheng Zhong- Abstract
Loading... -
+
EP08.02-036 - Selpercatinib Striking Response in a Case of Cerebral and Auditory Canal Metastasis of RET Fusion-Positive Non-Small-Cell Lung Cancer
Author(s): Diana Moreira Sousa- Abstract
Loading... -
+
EP08.02-044 - Adding Alectinib Rescues Progression on Osimertinib Due to Acquired ALK p.R1275Q Variant in EGFR p.L858R-mutated NSCLC
Author(s): Edyta Maria Urbanska- Abstract
Loading... -
+
EP08.02-045 - Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer
Author(s): Elaine Shum- Abstract
Loading... -
+
EP08.02-046 - Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
Author(s): Elio Gregory Pizzutilo- Abstract
Loading... -
+
EP08.02-047 - The Impact of CGP on the Decision-making Process in ALK+ aNSCLC After Failure of 2nd/3rd-Generation ALK TKIs
Author(s): Elizabeth Dudnik- Abstract
Loading... -
+
EP08.02-157 - Acquired EGFR Exon 19 Deletion Is a Resistance Mechanism to BRAF/MRK Inhibition in BRAF V600Emutant NSCLC
Author(s): Fang Wu- Abstract
Loading... -
+
EP08.02-048 - Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
Author(s): Federico Cappuzzo- Abstract
Loading... -
+
EP08.02-136 - Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer
Author(s): Juan Shen- Abstract
Loading... -
+
EP08.02-074 - Impact of Germline BRCA1/2 Alterations on EGFR Mutant Advanced Non-small Cell Lung Cancer Outcomes
Author(s): Jyoti D. Patel- Abstract
Loading... -
+
EP08.02-083 - Real World Treatment and Outcomes in EGFR-mutated Advanced Non-small Cell Lung Cancer Patients: A Nationwide Cohort for 1,932 Thai Patients
Author(s): Kakanan Tienchai- Abstract
Loading... -
+
EP08.02-010 - Low-Dose Dacomitinib as First-Line Therapy for Driver-Positive Advanced Non-small Cell Lung Cancer: A Multicenter Real-World Study in China
Author(s): Liang Gong- Abstract
Loading... -
+
EP08.02-158 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC
Author(s): Lin Wu- Abstract
Loading... -
+
EP08.02-092 - Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
Author(s): Xiaoling Xu- Abstract
Loading... -
+
EP08.02-118 - TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors
Author(s): Misako Nagasaka- Abstract
Loading... -
+
EP08.02-119 - RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer
Author(s): Nicole K Yun- Abstract
Loading... -
+
EP08.02-120 - MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
Author(s): Núria Jordana- Abstract
Loading... -
+
EP08.02-121 - The Landscape of Anti-neoplastic Drugs for Malignant Pleural Effusion in Non-small Cell Lung Cancer: A Systematic Review of Clinical Trials
Author(s): Obada Ehab Ababneh- Abstract
Loading... -
+
EP08.02-122 - Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)
Author(s): Oliver Illini- Abstract
Loading... -
+
EP08.02-124 - Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC
Author(s): PARVIN BEGUM- Abstract
Loading... -
+
EP08.02-088 - Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients
Author(s): Patricia Cruz Castellanos- Abstract
Loading... -
+
EP08.02-125 - Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer
Author(s): Paul Stockhammer- Abstract
Loading... -
+
EP08.02-126 - The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
Author(s): Petros Christopoulos- Abstract
Loading... -
+
EP08.02-129 - Closing the Gaps with Blood-Based Next Generation Sequencing
Author(s): Pratik Vijay Shah- Abstract
Loading... -
+
EP08.02-064 - ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
Author(s): Qing Zhou- Abstract
Loading... -
+
EP08.02-130 - Tegavivint Exhibits Antitumor Activity and Modulates Macrophage Phenotype in the Non-small Cell Lung Cancer Tumor Microenvironment
Author(s): Raghav Chandra- Abstract
Loading... -
+
EP08.02-150 - Molecular Heterogeneity of Compound Epidermal Growth Factor Receptor (EGFR) Mutations in Lung Adenocarcinoma (LAC)
Author(s): Rebecca Brooks- Abstract
Loading... -
+
EP08.02-131 - Alectinib after Crizotinib Failure in Patients with Advanced ALK‑Positive NSCLC: Results from the Spanish Early Access Program
Author(s): Reyes Bernabé-Caro- Abstract
Loading... -
+
EP08.02-132 - Fatal Interstitial lung disease induced by Osimertinib: a case report
Author(s): Ricardo José Cordeiro- Abstract
Loading... -
+
EP08.02-133 - Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report
Author(s): Ryo Morita- Abstract
Loading... -
+
EP08.02-166 - Brain Metastases in Patients with ALKrearranged or ROS1-fusion Non-small-Cell Lung Cancers in China
Author(s): Shaoyu Yang- Abstract
Loading... -
+
EP08.02-138 - SAFFRON: Ph3 Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
Author(s): Shun Lu- Abstract
Loading... -
+
EP08.02-139 - A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
Author(s): Shun Lu- Abstract
Loading... -
+
EP08.02-137 - Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment
Author(s): Shun Lu- Abstract
Loading... -
+
EP08.02-072 - The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs
Author(s): Adam Szpechcinski- Abstract
Loading... -
+
EP08.02-019 - Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Author(s): Alexander Spira- Abstract
Loading... -
+
EP08.02-041 - NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
Author(s): Alexander Drilon- Abstract
Loading... -
+
EP08.02-018 - Phase 1/2 Study of BLU-451, a Small Molecule Inhibitor of EGFR, in EGFR Exon 20 Insertion-Mutant Incurable Advanced Cancers
Author(s): Alexander Spira- Abstract
Loading... -
+
EP08.02-015 - The Utility of Liquid Biopsies for Management of Stage IV Non-small Cell Lung Cancer (NSCLC) in an Academic Community Medical Center
Author(s): Alisha Paro Maity- Abstract
Loading... -
+
EP08.02-014 - Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort
Author(s): Amanda Gibson- Abstract
Loading... -
+
EP08.02-013 - Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC
Author(s): Amanda Gibson- Abstract
Loading... -
+
EP08.02-037 - Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib.
Author(s): Anastasios Dimou- Abstract
Loading... -
+
EP08.02-011 - Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC
Author(s): Andrés Aguilar- Abstract
Loading... -
+
EP08.02-020 - Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation
Author(s): Hayato Mizuta- Abstract
Loading... -
+
EP08.02-123 - First Line Osimertinib in Lung Cancer Patients with Postoperative Recurrence
Author(s): Atsushi Osoegawa- Abstract
Loading... -
+
EP08.02-022 - Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen
Author(s): Bengisu Uluata Dayanc- Abstract
Loading... -
+
EP08.02-016 - Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
Author(s): Nicolas Girard- Abstract
Loading... -
+
EP08.02-145 - An Efficacy Analysis of Advanced Non Small Cell Lung Cancer With MET Exon 14 Skipping in the Real World
Author(s): Fei Teng- Abstract
Loading... -
+
EP08.02-076 - Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab
Author(s): Fenge Jiang- Abstract
Loading... -
+
EP08.02-053 - Non-small Cell Lung Cancer withMETExon14 Skipping Mutation: Literature Review of Real-World Evidence Data
Author(s): Encarnação Teixeira- Abstract
Loading... -
+
EP08.02-054 - Efficacy and Safety of TKI Dose Reduction - Can Less Mean More?
Author(s): Fernando Pereira da Silva- Abstract
Loading... -
+
EP08.02-056 - Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors
Author(s): Flávia Amaral Duarte- Abstract
Loading... -
+
EP08.02-058 - A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib - Croatian Experience
Author(s): Fran Seiwerth- Abstract
Loading... -
+
EP08.02-049 - A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
Author(s): Frans Opdam- Abstract
Loading... -
+
EP08.02-055 - Targeting Lung Adenocarcinoma Cells with a Novel Disulfide Reductase Inhibitor
Author(s): Fraser Johnson- Abstract
Loading... -
+
EP08.02-094 - Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial
Author(s): Gen Lin- Abstract
Loading... -
+
EP08.02-060 - How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry
Author(s): Giannis Mountzios- Abstract
Loading... -
+
EP08.02-059 - EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis
Author(s): Gilberto de Castro- Abstract
Loading... -
+
EP08.02-061 - Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?
Author(s): Grace Chazan- Abstract
Loading... -
+
EP08.02-062 - Evaluation of In Silico Tools to Determine Potential Actionability of Missense Variants with Experimental Therapies for NSCLC
Author(s): Grace Yujin Lee- Abstract
Loading... -
+
EP08.02-065 - Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations
Author(s): Hazel M O'Sullivan- Abstract
Loading... -
+
EP08.02-154 - Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial
Author(s): Hualin Chen- Abstract
Loading... -
+
EP08.02-004 - Aumolertinib in Treatment-Naïve EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY
Author(s): Huijuan Wang- Abstract
Loading... -
+
EP08.02-006 - Data from Real World to Evaluate the Efficacy of Almonertinib in EGFR-mutant NSCLC Patients
Author(s): Huijuan Wang- Abstract
Loading... -
+
EP08.02-005 - A Prospective Non-randomized Observational Study on Efficacy and Its Relative Factors of Pemetrexed Combined With EGFR-TKIs in NSCLC
Author(s): Huijuan Wang- Abstract
Loading... -
+
EP08.02-128 - Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial
Author(s): Hyungjun Park- Abstract
Loading... -
+
EP08.02-070 - High Incidence of Peridiagnosis Thromboembolic Events In Patients with BRAF Mutant Lung Cancer
Author(s): Inmaculada Aparicio Salcedo- Abstract
Loading... -
+
EP08.02-071 - Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort
Author(s): Ishjot Litt- Abstract
Loading... -
+
EP08.02-082 - Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
Author(s): Jae Yun Lee- Abstract
Loading... -
+
EP08.02-029 - Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
Author(s): James Chih-Hsin Yang- Abstract
Loading... -
+
EP08.02-080 - EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting
Author(s): Janakiraman Subramanian- Abstract
Loading... -
+
EP08.02-075 - Maintained Complete Response for 8+ Years with Erlotinib Alone in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion
Author(s): Jens Benn Sørensen- Abstract
Loading... -
+
EP08.02-068 - ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3)
Author(s): Jie Huang- Abstract
Loading... -
+
EP08.02-063 - SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
Author(s): Qing Zhou- Abstract
Loading... -
+
EP08.02-077 - Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumor Suppressor Genes
Author(s): Jie Wang- Abstract
Loading... -
+
EP08.02-002 - Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia
Author(s): Jie Tan- Abstract
Loading... -
+
EP08.02-081 - Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC
Author(s): Joel W. Neal- Abstract
Loading... -
+
EP08.02-079 - The Use of Lung Adenocarcinoma Patient-Derived Xenografts and Organoids to Study GDP-KRAS G12C Inhibitor Resistance
Author(s): Joshua Rosen- Abstract
Loading... -
+
EP08.02-161 - An Exploratory Study on Biomarkers Related to Primary Resistance Of EGFR-TKIs Therapy in Lung Cancer
Author(s): Lin Wu- Abstract
Loading... -
+
EP08.02-093 - Loss of Tumor Endothelial QKI Expression Results in Pronounced Reductions in Metastasis and Remodeling of the Tumor Microenvironment
Author(s): lincy edatt- Abstract
Loading... -
+
EP08.02-057 - Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after Resistance
Author(s): Lingxin Feng- Abstract
Loading... -
+
EP08.02-017 - Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data
Author(s): Lior Apter- Abstract
Loading... -
+
EP08.02-097 - Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina
Author(s): Luis Basbus- Abstract
Loading... -
+
EP08.02-099 - Liquid Biopsies as a Tool for Monitoring Patients with Metastatic ALK-positive NSCLC
Author(s): Maiken Parm Ulhoi- Abstract
Loading... -
+
EP08.02-108 - Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study
Author(s): Marina Chiara Garassino- Abstract
Loading... -
+
EP08.02-101 - Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study
Author(s): Maristella Bungaro- Abstract
Loading... -
+
EP08.02-102 - Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer
Author(s): Marta Garcia de Herreros- Abstract
Loading... -
+
EP08.02-110 - Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Tissue Biopsy
Author(s): Marta Arregui- Abstract
Loading... -
+
EP08.02-098 - Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC
Author(s): Martin Reck- Abstract
Loading... -
+
EP08.02-103 - Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience
Author(s): Ryan Ng- Abstract
Loading... -
+
EP08.02-104 - Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World
Author(s): Martina Lorenzi- Abstract
Loading... -
+
EP08.02-113 - Clinico-genomic Characteristics of Patients with Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Author(s): Masanobu Okahisa- Abstract
Loading... -
+
EP08.02-105 - KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer. Characteristics and Outcomes from a Danish Nationwide Observational Study
Author(s): Matilde Tejlbo Frost- Abstract
Loading... -
+
EP08.02-107 - Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer
Author(s): Matthew Villanueva, PharmD- Abstract
Loading... -
+
EP08.02-106 - KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
Author(s): Matthias Scheffler- Abstract
Loading... -
+
EP08.02-067 - Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Author(s): Meijuan Huang- Abstract
Loading... -
+
EP08.02-111 - RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial
Author(s): Melissa L Johnson- Abstract
Loading... -
+
EP08.02-084 - Evaluation of Tumor Heterogeneity (TH) as a Prognostic Biomarker in Osimertinib treated Non-Small Cell Lung Cancer Patients
Author(s): Karthikeyan Murugesan- Abstract
Loading... -
+
EP08.02-085 - In vitro Activity and Potential Resistance Mutations Against BI-4020, a 4th-generation EGFR-TKI
Author(s): Kenichi Suda- Abstract
Loading... -
+
EP08.02-089 - Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer
Author(s): Lauren Jones- Abstract
Loading... -
+
EP08.02-096 - Different Epidermal Growth Factor Receptor Inhibitor Generations Plus Antiangiogenic for EGFR-Mutated NSCLC: A Meta-Analysis
Author(s): Leen Al-Kraimeen- Abstract
Loading... -
+
EP08.02-090 - Sotorasib Drug-Drug Interactions: Essential Guidance Requested by Physicians Worldwide
Author(s): Leila-Sophie Otten- Abstract
Loading... -
+
EP08.02-160 - A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy
Author(s): Lin Wu- Abstract
Loading... -
+
EP08.02-109 - A Drug-Drug Interaction Study of Mobocertinib and Midazolam in Patients With Advanced Non-Small Cell Lung Cancer
Author(s): Michael J. Hanley- Abstract
Loading... -
+
EP08.02-117 - Online CME Improves Clinicians’ Ability to Identify and Manage Patients with NSCLC and EGFR Exon 20 Insertion Mutations
Author(s): Michelle Arielle Worst- Abstract
Loading... -
+
EP08.02-112 - Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province
Author(s): Michelle Liane Dean- Abstract
Loading... -
+
EP08.02-116 - Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors
Author(s): Miguel Villalona Calero- Abstract
Loading... -
+
EP08.02-114 - Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
Author(s): Moritz Glaser- Abstract
Loading... -
+
EP08.02-115 - A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan
Author(s): Motohiro Tamiya- Abstract
Loading... -
+
EP08.02-050 - A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis
Author(s): shencun Fang- Abstract
Loading... -
+
EP08.02-143 - Shortening of the Turn around time (TAT) in the Examination of Rapid On-Site cytologic Evaluation (ROSE) at transbronchial biopsy.
Author(s): Naoyuki Nogami- Abstract
Loading... -
+
EP08.02-038 - Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis
Author(s): Shuai Fu- Abstract
Loading... -
+
EP08.02-159 - Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
Author(s): Juan Li- Abstract
Loading... -
+
EP08.02-140 - MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
Author(s): Myung-Ju Ahn- Abstract
Loading... -
+
EP08.02-135 - Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)
Author(s): Silvia Garcia-Roman- Abstract
Loading... -
+
EP08.02-042 - EGFR-TKI +/- Antiangiogenics for EGFR-mutated Advanced NSCLC
Author(s): Laercio Lopes DaSilva- Abstract
Loading... -
+
EP08.02-087 - A 28-Years Old Pregnant Woman Diagnosed as ALK-Rearrangement Lung Adenocarcinoma With Multiple Brain Metastasis - Case Report
Author(s): Simona Laštíkova- Abstract
Loading... -
+
EP08.02-164 - The Effect of Metformin on Survival Outcomes of Advanced EGFR-mutant NSCLC Patients Treated with EGFR TKIs in Thailand
Author(s): Siriwimon Saichaemchan- Abstract
Loading... -
+
EP08.02-069 - A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases
Author(s): siyuan Huang- Abstract
Loading... -
+
EP08.02-141 - ‘Our’ EGFR population - experience in a secondary center
Author(s): Sofia Campos Silva- Abstract
Loading... -
+
EP08.02-030 - Tusamitamab Ravtansine in Patients with NSQ NSCLC and Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
Author(s): Sophie Cousin- Abstract
Loading... -
+
EP08.02-142 - Effects of Afatinib on the Treatment and Prognosis of Brain Metastasis in Advanced EGFR Mutation (+) NSCLC
Author(s): Sung Yong Lee- Abstract
Loading... -
+
EP08.02-144 - The Impact of CNS Recurrence on Post-recurrence Survival in Patients with EGFR-mutation-positive Non-small-cell Lung Cancer
Author(s): Tatsuro Okamoto- Abstract
Loading... -
+
EP08.02-171 - PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion‒Positive Metastatic Non‒Small Cell Lung Cancer (NSCLC)
Author(s): Rosario Garcia- Abstract
Loading... -
+
EP08.02-146 - Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation
Author(s): Toshio Fujino- Abstract
Loading... -
+
EP08.02-147 - Clinical Outcomes in Patients with or without Cell Cycle Gene Alterations in EGFR mutated Non-Small Cell Lung Cancer
Author(s): Turja Chakrabarti- Abstract
Loading... -
+
EP08.02-148 - Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer
Author(s): Victor Moreno- Abstract
Loading... -
+
EP08.02-149 - Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab
Author(s): Víctor Albarrán-Artahona- Abstract
Loading... -
+
EP08.02-151 - A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer
Author(s): Jin-Yuan Shih- Abstract
Loading... -
+
EP08.02-039 - An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib
Author(s): Xinyong Zhang- Abstract
Loading... -
+
EP08.02-163 - Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer
Author(s): Xiuning Le- Abstract
Loading... -
+
EP08.02-162 - Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
Author(s): Xiuning Le- Abstract
Loading... -
+
EP08.02-091 - Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
Author(s): Yan Li- Abstract
Loading... -
+
EP08.02-003 - Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis
Author(s): YanWei Li- Abstract
Loading... -
+
EP08.02-167 - Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters
Author(s): Yasi Xu- Abstract
Loading... -
+
EP08.02-155 - The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
Author(s): Yen Hsiang Huang- Abstract
Loading... -
+
EP08.02-021 - A Phase II Trial of Upfront Aumolertinib (HS-10296) plus Radiotherapy for EGFR Mutated Non-small-cell Lung Cancer Patients with Brain Metastases
Author(s): Yi Tang- Abstract
Loading... -
+
EP08.02-156 - Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US
Author(s): Yin Wan- Abstract
Loading... -
+
EP08.02-078 - Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)
Author(s): Ying Cheng- Abstract
Loading... -
+
EP08.02-001 - Concurrent Aumolertinib and Cerebral Radiotherapy as First-Line Treatment for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Author(s): Ying Wang- Abstract
Loading... -
+
EP08.02-086 - Randomized Double-blind Placebo-controlled trial of Nicotinamide and EGFR-TKIs for EGFR-mutated Lung Adenocarcinoma
Author(s): Young-Chul Kim- Abstract
Loading... -
+
EP08.02-168 - Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute
Author(s): Yuki Akazawa- Abstract
Loading... -
+
EP08.02-052 - Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E- Mutation Positive Metastatic NSCLC
Author(s): Yun Fan- Abstract
Loading... -
+
EP08.02-051 - High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
Author(s): Yun Fan- Abstract
Loading... -
+
EP08.02-152 - Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis
Author(s): Tianwei Xu- Abstract
Loading... -
+
EP08.02-153 - The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLC
Author(s): Tianwei Xu- Abstract
Loading... -
+
EP08.02-007 - Disease Burden and Clinical Outcomes of Advanced ROS1 Positive NSCLC with Different Fusion Partners
Author(s): Zihua Zou- Abstract
Loading... -
+
EP08.02-008 - Tumor Invasiveness and Clinical Outcomes between Metastatic ROS-1 and ALK Positive NSCLC
Author(s): Zihua Zou- Abstract
Loading... -
+
EP08.02-009 - Progression Pattern, Resistance Mechanism and Subsequent Therapy for ALK Positive NSCLC in the Era of Second—Generation ALK—TKIs
Author(s): Zihua Zou- Abstract
Loading... -
+
EP08.02-100 - Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression
Author(s): Ziyi Xu- Abstract
Loading... -
+
EP08.02-173 - Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings
Author(s): Joshua Sabari- Abstract
Loading... -
+
EP08.02-174 - RET Fusions as Primary Oncogenic Drivers and Secondary Acquired Resistance to EGFR TKI in a Large Cohort of Non-Small-Cell Lung Cancers
Author(s): Chunyue Wang- Abstract
Loading...
-
+
EP08.03 - Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease
- Presentations: 8
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.03-002 - Local Ablative Therapy in Oligoprogressive NSCLC - Results from a Tertiary Cancer Center of India
Author(s): Anil Tibdewal- Abstract
Loading... -
+
EP08.03-001 - A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases
Author(s): chunyu He- Abstract
Loading... -
+
EP08.03-005 - HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours
Author(s): Fiona McDonald- Abstract
Loading... -
+
EP08.03-004 - Outcomes of Oligometastatic Non-Small Cell Lung Cancer Patients Undergoing Surgical Resection: A Single Center Experience
Author(s): Fulden Gorguner- Abstract
Loading... -
+
EP08.03-003 - Surgery for Primary Tumor is Associated with Prolonged Overall Survival in Patients with Oligometastatic NSCLC
Author(s): Jose Francisco Corona-Cruz- Abstract
Loading... -
+
EP08.03-007 - Spontaneous Regression in Metastatic Non-small Cell Lung Cancer: A Case Report
Author(s): Maria La Mantia- Abstract
Loading... -
+
EP08.03-006 - Survival After Radical Treatment of Oligometastatic Non-small Cell Lung Cancer: A Multicenter Analysis
Author(s): Raphael S. Werner- Abstract
Loading... -
+
EP08.03-008 - Whether Immunotherapy Should Be Maintained or Not After Acquired Resistance in Advanced Nsclc
Author(s): Huayan Huang- Abstract
Loading...
-
+
EP08.04 - Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy
- Presentations: 6
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.04-001 - Weekly versus 3-Weekly Regimens of Carboplatin and Paclitaxel in Metastatic NSCLC: A Real-World Data
Author(s): Barliz Waissengrin- Abstract
Loading... -
+
EP08.04-002 - Australian Vinorelbine Use in Advanced Lung cancer (The AVAL Study)
Author(s): Grace Gard- Abstract
Loading... -
+
EP08.04-005 - Phase II Study of Ramucirumab and Docetaxel for NSCLC Patients with Malignant Pleural Effusion
Author(s): Shinnosuke Takemoto- Abstract
Loading... -
+
EP08.04-004 - Impact of Comorbidity Scores on Overall Survival in Advanced Non-Small Cell Lung Cancer Patients -A Real-World Experience from Eastern India
Author(s): Srikanth Goud Mamidi- Abstract
Loading... -
+
EP08.04-003 - A Simple Clinical Prediction Score to Determine Response to First Line Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
Author(s): Chawalit Chayangsu- Abstract
Loading... -
+
EP08.04-006 - Risk Factors of Chemotherapy-Induced Severe Neutropenia in Elderly Lung Cancer: Data From a Regional Hospital in Thailand
Author(s): Sunee Neesanun- Abstract
Loading...
-
+
EP08.05 - Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy
- Presentations: 4
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.05-001 - Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation
Author(s): David Y. Mak- Abstract
Loading... -
+
EP08.05-003 - Evaluation of Dose Changes in Different Periods after 125I Seed Implantation in Lung Cancer
Author(s): han xian wei- Abstract
Loading... -
+
EP08.05-002 - Sequencing of T cell Receptor Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis
Author(s): Hao Zeng- Abstract
Loading... -
+
EP08.05-004 - The Optimal Intervention Timing of Hypofractionated Stereotactic Radiotherapy for EGFR Mutated NSCLC Patients With Limited Brain Metastases
Author(s): Lin Zhou- Abstract
Loading...
-
+
EP09.01 - Nursing and Allied Health Professionals
- Type: E-Poster
- Track: Nursing and Allied Health Professionals
- Presentations: 2
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP09.01-001 - International Collaboration for Thoracic Oncology Education
Author(s): Beth Sandy- Abstract
Loading... -
+
EP09.01-002 - Patient with Immune-associated Dermatomyositis Caused byAdvanced NSCLC Treated with ICIs
Author(s): Li Han- Abstract
Loading...
-
+
EP10.01 - Palliative and Supportive Care
- Type: E-Poster
- Track: Palliative and Supportive Care
- Presentations: 20
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP10.01-010 - Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL)
Author(s): ZHEN WANG- Abstract
Loading... -
+
EP10.01-003 - Non-Small Cell Lung Cancer Treatment Preferences Among EGFR Mutation Patients and Physicians in Japan
Author(s): Akira Inoue- Abstract
Loading... -
+
EP10.01-004 - Perspectives of Patients with Metastatic Lung Cancer on Symptom Screening and Patient-Reported Symptom Trajectory Data
Author(s): Amir H. Safavi- Abstract
Loading... -
+
EP10.01-011 - Prognostic Impact of Body Composition Phenotypes in Non-small Cell Lung Cancer Patients Receiving First-Line Pembrolizumab
Author(s): Ilaria Trestini- Abstract
Loading... -
+
EP10.01-012 - Geriatric Assessment in Patients Undergoing Lung Cancer Surgery and Their Family Caregivers
Author(s): Jae Yul Kim- Abstract
Loading... -
+
EP10.01-001 - Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Lung Cancer: Dose-Response Effect and Toxicity
Author(s): Kaicheng Pan- Abstract
Loading... -
+
EP10.01-013 - Erector Spinae Plane Block for Post-thoracotomy Analgesia; Comparison with Intercostal Block; Preliminary Results
Author(s): Kubra Alphan Kavak- Abstract
Loading... -
+
EP10.01-002 - The Effect of Group Rehabilitation Training in the Ward on the Psychological Status and Quality of Life of Lung Cancer Patients
Author(s): Li Li- Abstract
Loading... -
+
EP10.01-015 - The Role of CT-Scan as a Body Composition Tool in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
Author(s): Anna Maria Morelli- Abstract
Loading... -
+
EP10.01-020 - Nutritionassessment for With Common Cancer Patients in a Cancer Hospital of China
Author(s): Mengting Chen- Abstract
Loading... -
+
EP10.01-014 - A Multidisciplinary Team to Manage Patients with Lung Cancer and Opioid Use Disorder
Author(s): Michael Huber- Abstract
Loading... -
+
EP10.01-005 - Australian Lung Cancer Survivors Experiences of Novel Treatments, Healthcare, and Ongoing Physical and Psychological Needs
Author(s): Rebekah Laidsaar-Powell- Abstract
Loading... -
+
EP10.01-006 - Differences In Toxicity Among Platinum-Based Combinations As Reported By Non-Small Cell Lung Cancer (NSCLC) Patients
Author(s): Paris Kosmidis- Abstract
Loading... -
+
EP10.01-007 - Real World Data Comparing Lung Cancer Side-Effects Between Past/Current Smokers And Never Smokers
Author(s): Paris Kosmidis- Abstract
Loading... -
+
EP10.01-016 - Cachexia’s Impact on Immunotherapy Dose Reduction, Treatment Discontinuation, and Survival: a Systematic Review
Author(s): Richard J. E. Skipworth- Abstract
Loading... -
+
EP10.01-008 - Examining Social Determinants of Health Among Newly Diagnosed Lung Cancer Patients Contacted for Early Specialist Palliative Care Consultation
Author(s): Seema King- Abstract
Loading... -
+
EP10.01-017 - Use of Lalaby in Lung Cancer Patients to Trace Performance from Phone Sensors and Reported Outcomes Involving Quality of Life
Author(s): Teresa Soria-Comes- Abstract
Loading... -
+
EP10.01-019 - Rowing Against Cancer: From a Support Project to a Research Program. Perspectives and Challenges of Rowing in Metastatic Lung Cancer Patients
Author(s): Tindara Franchina- Abstract
Loading... -
+
EP10.01-009 - The Impact of the COVID-19 Pandemic on Palliative Care for Cancer: A Preliminary Cross-Country Survey of Clinical Oncologists
Author(s): Yu Wang- Abstract
Loading... -
+
EP10.01-018 - Thromboprophylaxis for Lung Cancer Patients: Results From ACT4CAT Trial
Author(s): Nikolaos G Tsoukalas- Abstract
Loading...
-
+
EP11.01 - Pathology - Genomics & Analytics
- Type: E-Poster
- Track: Pathology - Genomics & Analytics
- Presentations: 12
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP11.01-011 - Clinical Application of Liquid Biopsy for Assessing Early EGFR Mutation Detection in Non-Small Cell Lung Carcinoma
Author(s): AMBER RATHOR- Abstract
Loading... -
+
EP11.01-002 - Malignant Pleural Effusion Cell Blocks Are Reliable Resources for PD-L1 Analysis in Advanced Lung Adenocarcinomas
Author(s): Aruna Nambirajan- Abstract
Loading... -
+
EP11.01-004 - An Effective Two-step Reflex Test for 10 Biomarkers Analysis in Non-small Cell Lung Cancer
Author(s): Giacomo Pelizzari- Abstract
Loading... -
+
EP11.01-013 - Genomic Landscape of Pulmonary Sarcomatoid Carcinoma
Author(s): Hyun Jung Kwon- Abstract
Loading... -
+
EP11.01-007 - Tracking ROS1 Fusions in NSCLC - Mirage or Truth When Screening the Desert
Author(s): Johanna Mattsson- Abstract
Loading... -
+
EP11.01-006 - Setting Up an Ultra-Fast Next-Generation Sequencing Approach as a Reflex Testing at Diagnosis in Non-squamous Non-small Cell Lung Cancer
Author(s): Christophe Bontoux- Abstract
Loading... -
+
EP11.01-005 - Ultra-Fast Gene Fusion Assessment as a Reflex Testing in Daily Clinical Practice for Advanced Non-small Cell Lung Cancer Patients
Author(s): Véronique Hofman- Abstract
Loading... -
+
EP11.01-012 - Genomic Landscape of Liquid Biopsy in Advanced Lung Cancer Patients, an Indian Experience
Author(s): Shivani Sharma- Abstract
Loading... -
+
EP11.01-014 - Optimizing Targetable Gene Screening by Sequential Multi-platform Detection Applied to Driver-negative mNSCLC Patients Detected by DNA-NGS
Author(s): Yaxi Wang- Abstract
Loading... -
+
EP11.01-008 - Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System
Author(s): Kanako Shinada- Abstract
Loading... -
+
EP11.01-003 - Advanced Non Small Cell Lung Cancer With EGFR Exon 20 Insertion Gene Mutation
Author(s): NGUYEN SON LAM- Abstract
Loading... -
+
EP11.01-010 - A Prospective Validation Study of Lung Cancer Gene Panel Testing Using Cytological Specimens
Author(s): Kei Morikawa- Abstract
Loading...
-
+
EP11.02 - Pathology - New Technology
- Type: E-Poster
- Track: Pathology - New Technology
- Presentations: 2
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP11.02-001 - Natural Language Processing to Abstract Preneoplastic and Incidental Pulmonary Lesions from Pathology Reports
Author(s): Jessica Petricca- Abstract
Loading... -
+
EP11.02-002 - A Comparative Study of PD-L1 Scoring: Humans versus AI
Author(s): Markus Plass- Abstract
Loading...
-
+
EP11.03 - Pathology - Tumour Biology
- Type: E-Poster
- Track: Pathology - Tumour Biology
- Presentations: 4
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP11.03-001 - Loss of SUSD2 Expression in Lung Adenocarcinoma Correlates with Solid Pattern, Higher Histological Grading and Higher Ki-67 Cycling Index
Author(s): Hangjun Wang- Abstract
Loading... -
+
EP11.03-004 - Identification of Filigree Pattern Increases Diagnostic Accuracy of Micropapillary Pattern on Frozen Section for Lung Adenocarcinoma
Author(s): Shengnan Zhao- Abstract
Loading... -
+
EP11.03-002 - Prognostic Significance of YAP1 and Its Association with Neuroendocrine Markers in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNEC)
Author(s): xujie Sun- Abstract
Loading... -
+
EP11.03-003 - Adenocarcinoma Grade Correlates with PD-L1 and TP53, but not EGFR/KRAS Status and Diagnostic Yield: Analysis of 346 Cases
Author(s): Yu Zhi Zhang- Abstract
Loading...
-
+
EP11.04 - Pathology - Tumour Diagnostics
- Type: E-Poster
- Track: Pathology - Tumour Diagnostics
- Presentations: 2
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP11.04-001 - Cytokeratin 5-Positive Pulmonary Adenocarcinoma: A Study with Resected Specimens
Author(s): Akihiko Yoshizawa- Abstract
Loading... -
+
EP11.04-002 - The Histopathological Reasons for Better Survival of Patients with Lepidic Pattern Dominant Adenocarcinoma
Author(s): Ismail Sarbay- Abstract
Loading...
first
prev
